Watch routine care for drug combinations that quietly make cancer treatment worse
Some everyday medicines, such as antibiotics or steroids, seem to blunt immunotherapy. Automatically scanning health records for such harmful pairs would catch them years earlier.
Antibiotics, proton-pump inhibitors and corticosteroids are associated with worse outcomes on checkpoint inhibitors in retrospective series, yet these signals took years to surface. A pharmacovigilance-style system that continuously screens clinico-genomic databases for concomitant medications associated with reduced efficacy (not just toxicity) would generate hypotheses for confirmation and, where confirmed, guideline warnings.
- Too many combinations to test · There are thousands of possible drug pairs and sequences. Trials can test a few dozen a year.
- Weak real-world evidence and registries · We do not reliably know what happens to patients after approval, so we cannot tell which drugs deliver in practice.
Pages like this
not linked directly; found by shared links- IdeaEmulate combination trials from real-world data to triage which ones to run
Shares Tempus AI, Too many combinations to test, Weak real-world evidence and registries, Real-world evidence.
- IdeaValidate real-world progression against central imaging review
Shares Tempus AI, Weak real-world evidence and registries, Real-world evidence.
- IdeaA global federated real-world evidence network at regulatory grade
Shares Tempus AI, Weak real-world evidence and registries, Real-world evidence.
- IdeaA registry of every treatment sequence patients actually receive, with outcomes
Shares Too many combinations to test, Weak real-world evidence and registries, Real-world evidence.
- IdeaSubscription pricing for checkpoint inhibitors: fixed national fee, unlimited use
Shares Nivolumab, Pembrolizumab, Immune checkpoint inhibitors.
- IdeaRestore weight-based dosing and vial sharing for immunotherapy in the label
Shares Nivolumab, Pembrolizumab, Immune checkpoint inhibitors.
- IdeaAn advance market commitment for PD-1 biosimilars for lower-income countries
Shares Nivolumab, Pembrolizumab, Immune checkpoint inhibitors.
- IdeaA real-world sequencing analysis within a year of every new approval
Shares Too many combinations to test, Weak real-world evidence and registries, Real-world evidence.